期刊文献+

辛伐他汀预处理对脓毒症大鼠凝血功能及肝脏C-反应蛋白的影响 被引量:10

Effects of simvastatin pretreatment on coagulation function and C - reactive protein of liver in septic rats
下载PDF
导出
摘要 目的观察辛伐他汀预处理对脓毒症大鼠凝血功能及肝脏C-反应蛋白(CRP)的影响。方法采用盲肠结扎穿孔术(CLP)制备脓毒症大鼠模型。清洁级雌性Wistar大鼠80只被随机分为正常对照组(8只)、假手术组(6、24、48h各8只)、脓毒症模型组(6、24、48h各8只)和辛伐他汀预处理组(6、24、48h各8只),除正常对照组外,其余各组于CLP术前给予生理盐水或辛伐他汀20mg,/(kg·d)(溶于1mL蒸馏水),灌胃连续2周,各组分别于CLP术后6、24、48h后活杀动物8只,留取血液及肝组织标本。观察脓毒症大鼠-般表现并测定脓毒症大鼠白细胞计数(WBC)及血小板计数(PLT)、组织因子(TF)、纤溶酶原激活物抑制物-1(PAI-1)、肝脏CRP等指标。结果辛伐他汀预处理可以降低脓毒症大鼠TF、PAI-1水平,减少PLT消耗,同时降低肝脏组织CRP水平的表达。结论辛伐他汀预处理能够改善脓毒症大鼠的凝血功能;减轻肝脏炎症反应,保护肝脏功能。 Objective To observe the effects of simvastatin pretreatment on coagulation function and C - reactive protein of liver in septic rats. Methods In this experiment, we established the rat model of sepsis induced by cecal ligation and puncture. Eighty clean healthy female Wistar rats were chosen and divided into four groups at random: nomal group, sham group, sepsis model group and prevention group. Except normal group, saline or 20 mg/( kg ·d) simvastatin( 1 mL sterile water for injection) was injected to their stomaches for two weeks before CLP. Each group killed eight rats effectively at 6 h, 24 h, 48 h point and collected blood samples and liver tissue specimens. Monitor the general situation of rats in each group and examine white blood cell, platelet count, the changes of TF and PAl- 1 in serum and the level of CRP in liver tissue in each group. Results Pretreatment with simvastatin could inhibit the production of tissue factor and plasminogen activator inhibitor - 1 in the serum, decrease consumption of platelets. At the same time, it could descend the lever of C - reactive protein of liver. Conclusion Pretreatment with simvastatin could improve the coagulation function, alleviate the degree of liver inflammation and protect liver function.
出处 《中国急救医学》 CAS CSCD 北大核心 2012年第8期718-721,I0003,共5页 Chinese Journal of Critical Care Medicine
关键词 脓毒症 血小板计数 组织因子 纤溶酶原激活物抑制物-1(PAI-1) C-反应蛋白(CRP) Sepsis Platelet count Tissue factor Plasminogen activator inhibitor - 1( PAl - 1 ) C - reactive protein (CRP)
  • 相关文献

参考文献9

二级参考文献48

  • 1胡森,盛志勇,薛立波,周宝桐,陆江阳,晋桦,于燕,孙晓床,黎君友,郑玉清,熊德鑫.多器官功能障碍综合征动物模型的系列研究[J].解放军医学杂志,1996,21(1):5-9. 被引量:57
  • 2胡森,盛志勇,林洪远,姚咏明,薛立波,王谊冰,孙世荣,祝晓枫.多器官功能障碍综合征早期诊断依据和实验室预警指标的探讨[J].解放军医学杂志,1996,21(1):13-16. 被引量:18
  • 3胡森,盛志勇,周宝桐,薛丽波,晋桦,于燕,陆江阳,孙晓庆,孙世荣,黎君友,王亚平,祝晓枫,郑玉清.双相迟发多器官功能不全综合征(MODS)动物模型的研究[J].中华创伤杂志,1996,12(2):102-106. 被引量:50
  • 4王平 孟宪钧 等.一种实验性多器官衰竭动物模型的研究[J].中华实验外科杂志,1987,4(2):70-71.
  • 5潘世成 罗正曜.休克,第1版[M].北京:人民卫生出版社,1982.502.
  • 6胡森 盛志勇 等.创后多系统器官衰竭(MODS)动物模型的实验研究[J].中华整形外科杂志,1992,8:2-6.
  • 7陆江阳 梁延杰 等.一种改进的酵母多糖素所致大鼠多器官衰竭的实验模型[J].解放军医学杂志,1991,16:451-453.
  • 8Hoesel LM,Gao H,Ward PA.New insights into cellular mechanisms during sepsis.Immunol Res,2006,34 (2):133-141.
  • 9Meziani F,Tesse A,Andriantsitohaina R.Microparticles are vectors of paradoxical information in vascular cells including the endothelium:role in health and diseases.Pharmacological Reports,2008,60(1):75-84.
  • 10Hubbard WJ,Choudhry M,Schwacha MG,et al.Cecal Ligation and Puncture.Shock,2005,24(suppl 1):52-57.

共引文献63

同被引文献106

  • 1Roland Andersson.Acute lung injury and ARDS in acute pancreatitis: Mechanisms and potential intervention[J].World Journal of Gastroenterology,2010,16(17):2094-2099. 被引量:66
  • 2聂振汪.浅谈凝血功能检测在评估肝脏受损程度中的临床价值[J].求医问药(下半月),2013(2):42-42. 被引量:3
  • 3曲海,李艳.浅谈难治性脓毒症休克的临床特征和治疗特点[J].当代医药论丛,2014,12(1):136-137. 被引量:4
  • 4刘大为.危重病医学[M].北京:中国协和医科大学出版社,2000.211.
  • 5Chello M,Anselmi A,Spadaccio C,et al. Simvastatin increasesneutrophil apoptosis and reduces inflammatory reaction after coro-nary surgery[ J]. Ann Thorac Surg, 2007, 83(4) : 1374 - 1380.
  • 6Kagami S, Kanari H, Suto A, et al. HMG-CoA reductase inhibitorsimvastatin inhibits proinflammatory cytokine production from mu-rine mast cells[ J]. Int Arch Allergy Immunol, 2008, 146( Suppl\):6l -66.
  • 7Bums EM, Smelser LK, Then JE, et al. Short term statin treat-ment improves survival and differentially regulates macrophage -mediated responses to Staphylococcus aureus [ J ] . Curr Pharm Bio-technol, 2013,14(2) : 233 -241.
  • 8Gonzdlez CM, Luna HA, Morales MP, et al. Statin anti - inflam-matory therapy in septic patients[ J]. Cri Care, 2008.
  • 9Krysiak R,Okopie6 B,Herman Z. Effects of HMG - CoA reduc-tase inhibitors on coagulation and fibrinolysis processes [ J ].Drugs, 2003, 63(17) : 1821 -1854.
  • 10Abraham E. Tissue factor inhibition and clinical trial results of tis-sue factor pathway inhibitor in sepsis[ J]. Crit Care Med,2000,28(9 Suppl) : S31 -33.

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部